The brief
Both the FDA and the European Medicines Agency have placed the therapy on an expedited review pathway. U.S. Key points and original sources are listed below.
- Both the FDA and the European Medicines Agency have placed the therapy on an expedited review pathway.S1
- U.S. pharmaceutical firms Merck and Moderna announced encouraging results Wednesday from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.S2
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trialS3
